OS Therapies (NYSEAMERICAN:OSTX) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of OS Therapies (NYSEAMERICAN:OSTX) in a research note issued to investors on Monday morning,Benzinga reports. D. Boral Capital currently has a $20.00 target price on the stock.

A number of other brokerages have also issued reports on OSTX. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Lake Street Capital reduced their target price on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.50.

OS Therapies Trading Up 8.9%

Shares of OSTX stock opened at $1.71 on Monday. The firm has a market capitalization of $60.21 million, a price-to-earnings ratio of -2.09 and a beta of -3.80. The business’s 50-day moving average price is $1.40 and its 200-day moving average price is $1.75. OS Therapies has a 12 month low of $1.12 and a 12 month high of $2.57.

Institutional Trading of OS Therapies

Several institutional investors have recently added to or reduced their stakes in OSTX. XTX Topco Ltd bought a new stake in OS Therapies in the second quarter valued at approximately $63,000. Bridgeway Capital Management LLC bought a new position in OS Therapies during the 2nd quarter worth approximately $47,000. Ground Swell Capital LLC bought a new position in OS Therapies during the 3rd quarter worth approximately $40,000. CM Management LLC lifted its position in shares of OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $784,000 after purchasing an additional 25,000 shares during the period. Finally, Two Sigma Investments LP acquired a new position in shares of OS Therapies in the 3rd quarter worth approximately $169,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.